Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4642485
Max Phase: Preclinical
Molecular Formula: C23H28ClN7
Molecular Weight: 437.98
Molecule Type: Unknown
Associated Items:
ID: ALA4642485
Max Phase: Preclinical
Molecular Formula: C23H28ClN7
Molecular Weight: 437.98
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)c1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cn2)ncc1Cl
Standard InChI: InChI=1S/C23H28ClN7/c1-16(2)18-6-4-5-7-20(18)27-22-19(24)15-26-23(29-22)28-21-9-8-17(14-25-21)31-12-10-30(3)11-13-31/h4-9,14-16H,10-13H2,1-3H3,(H2,25,26,27,28,29)
Standard InChI Key: SZRNZUUUCFGQSQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 437.98 | Molecular Weight (Monoisotopic): 437.2095 | AlogP: 4.89 | #Rotatable Bonds: 6 |
Polar Surface Area: 69.21 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.64 | CX Basic pKa: 7.65 | CX LogP: 5.38 | CX LogD: 4.94 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.57 | Np Likeness Score: -1.57 |
1. Wang Y, Chen X, Yan Y, Zhu X, Liu M, Liu X.. (2020) Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity., 63 (6): [PMID:32129996] [10.1021/acs.jmedchem.9b02121] |
Source(1):